

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BeiGene, Ltd.**

**百濟神州有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 06160)**

## **PROPOSED CHANGE OF ENGLISH NAME OF COMPANY**

Reference is made to the announcement of the Company dated August 7, 2024 in respect of, inter alia, the proposed change of domicile and Continuation (the “**Continuation Announcement**”). Unless otherwise specified, capitalized terms in this announcement shall have the same meanings as the defined terms in the Continuation Announcement.

In connection with the Continuation, the Board proposes to change the English name of the Company from “BeiGene, Ltd.” to “BeOne Medicines Ltd.” (the “**Proposed Change of English Name of the Company**”) and adopt the Proposed Swiss Articles incorporating the Proposed Change of English Name of the Company. The Chinese name of the Company will remain unchanged.

### **Reasons for the Proposed Change of English Name of the Company**

The Board considers that the new English name confirms the Company’s commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. The Board believes that the Proposed Change of English Name of the Company is in the interests of the Company and the Shareholders as a whole.

### **Conditions of the Proposed Change of English Name of the Company**

The Proposed Change of English Name of the Company is conditional upon:

- (i) the Conditions described in the Continuation Announcement having been fulfilled;
- (ii) the approval of the Adoption of the Proposed Swiss Articles (including the Proposed Change of English Name of the Company) by the Shareholders at the EGM; and
- (iii) the Company being registered in the commercial register of the Canton of Basel-City, Switzerland, under the Proposed Change of English Name of the Company on the date on which the Continuation becomes effective, as reflected in the commercial register excerpt issued on the effective date of the Continuation.

Subject to the satisfaction of the conditions set out above, the Proposed Change of English Name of the Company will take effect concurrently with the effectiveness of the Continuation from the date of registration of the Continuation in the commercial register of the Canton of Basel-City, Switzerland. The Company will then carry out the necessary filing procedures with the Companies Registry of Hong Kong.

### **Effects of the Proposed Change of English Name of the Company**

The Proposed Change of English Name of the Company will not affect any of the rights of the Shareholders. All existing certificates of securities in issue bearing the present name of the Company shall, after the Proposed Change of English Name of the Company becoming effective, continue to be evidence of title to such securities and valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for exchange of the existing certificates of securities for new certificates bearing the new English name of the Company. Once the Proposed Change of English Name of the Company becomes effective, new certificates of securities may be issued in the new name of the Company. In addition, subject to the confirmation of the HKEx, the English stock short name for trading in the shares of the Company will also be changed after the Proposed Change of English Name of the Company becomes effective.

### **The EGM**

The EGM will be convened and held for the Shareholders to consider and, if thought fit, approve (i) the Continuation; (ii) the Adoption of the Proposed Swiss Articles (including the Proposed Change of English Name of the Company); and (iii) the Election of the Swiss Auditor and Approval of Related Audit Services and Remuneration. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder has a material interest in (i) the Continuation; (ii) the Adoption of the Proposed Swiss Articles (including the Proposed Change of English Name of the Company); and (iii) the Election of Swiss Auditor and Approval of Related Audit Services and Remuneration, which is materially different from the other Shareholders. No Shareholder is therefore required to abstain from voting in respect of the proposed resolutions at the EGM.

The circular containing, among other things, further details of (i) the Continuation; (ii) the Adoption of the Proposed Swiss Articles (including the Change of English Name of the Company); and (iii) the Election of Swiss Auditor and Approval of Related Audit Services and Remuneration, together with a notice convening the EGM will be dispatched to the Shareholders in accordance with the HK Listing Rules.

**Shareholders and potential investors of the Company should note that the Continuation, the Adoption of the Proposed Swiss Articles (including the Proposed Change of English Name of the Company) and the Election of Swiss Auditor and Approval of Related Audit Services and Remuneration are conditional upon satisfaction of the respective conditions precedent as set out in the respective paragraphs headed “Conditions of the Continuation, the Adoption of the Proposed Swiss Articles and the Election of Swiss Auditor and Approval of Related Audit Services and Remuneration” detailed in the Continuation Announcement, and “Conditions of the Proposed Change of English Name of the Company” detailed in this announcement. Accordingly, the Continuation, the Adoption of the Proposed Swiss Articles (including the Proposed Change of English Name of the Company) and the Election of Swiss Auditor and Approval of Related Audit Services and Remuneration may or may not proceed.**

By order of the Board  
**BeiGene, Ltd.**  
**Mr. John V. Oyler**  
*Chairman*

Hong Kong, November 14, 2024

*As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.*